Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT04864145

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04864145
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04864145. Randomized; single masking; primary purpose treatment. Start 2021-05-21 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation
Acronym
SEASON-AR
Condition
Aortic Valve Disease
Intervention (Device)
Transcatheter Aortic Valve Implantation
Intervention (Drug)
Medical therapy
Lead sponsor
Nanjing First Hospital, Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct04864145
Content hash
0a46b00c66e969bd3c2abcdab4d90f76fa41621954a5e44c76f6519ba51f29d5